February 12, 2016
Use of a new drug-eluting balloon in the side branch after deployment of a drug-eluting stent yielded a low rate of late lumen loss and restenosis at the side branch ostium, according to 6-month angiographic follow-up results of the DEBSIDE trial.
The prospective, nonrandomized, multicenter study included 52 patients with de novo bifurcation lesions at eight centers in France. Between May 2012 and July 2016, all patients underwent DES placement (Nile PAX stent) followed by final DEB inflation (Danubio Balloon, Minvasys), based on size of the side branch. Eligible participants were aged older than 18 years, with clinical evidence of ischemic heart disease, stable/unstable angina with signs of ischemia, silent functional ischemia or a positive functional test. Required lesion length was 6 mm or smaller in the side branch; and the reference vessel diameter had to be 2.5 mm to 3.5 mm for the main branch and 2 mm to 3 mm for the side branch.